Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
Status:
Recruiting
Trial end date:
2023-02-24
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of miricorilant
in the presence and absence of the strong cytochrome P450 [(CYP) 2C19] inhibitor,
fluvoxamine, in healthy participants. Participants will receive a single dose of miricorilant
under fed conditions with a standard breakfast after an overnight fast alone and in
combination with once-daily doses of fluvoxamine. Blood samples will be collected at regular
intervals for PK and safety analysis between admission and discharge from the clinical unit.